Umbilical Cord Blood Transplantation for Patients with Idiopathic and Inherited Bone Marrow Failure Disorders

Read full text Summarise with VIRAT
Authors: Simona Pagliuca, Arthur Sterin
Cited by: 0
References: 88

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Umbilical cord blood transplantation (UCBT) offers a viable hematopoietic stem cell source for patients with idiopathic and inherited bone marrow failure (BMF) syndromes lacking matched related donors (MRDs) or matched unrelated donors (MUDs). Although its use has declined with the rise of haploidentical transplantation, UCBT remains crucial for select patients, especially children. The approach is associated with rapid donor availability, low graft versus host disease (GvHD) risk, and favorable outcomes in matched settings. Retrospective data and prospective trials demonstrate encouraging survival, particularly with appropriate cell dose, minimal human leukocyte antigen (HLA) mismatch, and fludarabine (Flu)-based reduced-intensity conditioning (RIC) regimens. Specific syndromes such as Fanconi anemia (FA), severe aplastic anemia (SAA), dyskeratosis congenita (DC), and Diamond–Blackfan anemia (DBA) highlight distinct challenges and considerations in UCBT application. While matched sibling UCBT shows excellent outcomes, unrelated UCBT requires careful patient selection and transplant expertise. As research advances and transplant protocols evolve, UCBT remains a critical option in the curative landscape for patients with BMF syndromes.

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Blood disorders and treatments Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Springer eBooks
Pages
185–200
Publication date
25 March 2026
Language
EN
Document type
Book chapter